Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01162733 · ClinicalTrials.gov registry record · NA

Loading Vancomycin Doses in the Emergency Department

A NA study, sponsored by Christiana Care Health Services.

Completed
Registry status
NA
Development phase
99
Enrollment target

NCT01162733 is a NA study that has completed, run by Christiana Care Health Services. The registered enrollment target is 99 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01162733, a NA study, has completed, sponsored by Christiana Care Health Services.

COMPLETED
Registry status
NA
Development phase
99 participants
Enrollment target

Study Summary

In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently there is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the IDSA put forth new recommendations for vancomycin dosing in order to achieve therapeutic levels more rapidly. It has been hypothesized that if therapeutic levels are reached more rapidly then patients will in turn have better clinical outcomes and that the development of resistant organisms will be decreased. Methicillin resistant Staphylococcus aureus (MRSA) has emerged as one of the most deadly pathogens that are currently plaguing our patient population. Vancomycin is one of only a few antibiotics that are effective for treating MRSA. It is imperative that the ED physicians consistently and correctly dose vancomycin in order to give the patients the best chance to fight infection while helping to prevent further resistance in this already highly resistant organism. It is believed this study will reveal that the new dosing recommendations by the IDSA will lead to the achievement of therapeutic levels more rapidly. This information will in turn help to convince ED physicians that a change in current clinical practice is warranted and ultimately lead to better clinically outcomes for the patients.

Interventions

  • DRUG Vancomycin

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2010-07
Est. Completion 2012-06
Phase NA

Sponsor

Christiana Care Health Services

82 total trials

What the Registry Record Tells You About NCT01162733

The ClinicalTrials.gov registry entry for NCT01162733 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Christiana Care Health Services, which has 82 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Vancomycin is the first listed.

NCT01162733 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01162733 about?

NCT01162733 is a clinical study titled "Loading Vancomycin Doses in the Emergency Department". In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently there is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the IDSA put forth new recommendations for vancomycin dosing in order to achieve therapeutic levels more rapidly. It has been h...

What is the current status of trial NCT01162733?

This trial is currently completed. It is a NA study. The enrollment target is 99 participants. The study started on 2010-07. Estimated completion is 2012-06.

What interventions are being tested in trial NCT01162733?

The interventions under investigation include: Vancomycin (DRUG).

Who is sponsoring clinical trial NCT01162733?

This trial is sponsored by Christiana Care Health Services, which has 82 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.